Venetoclax Plus Rituximab can Achieve Durable Treatment-Free Remission in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-2 inhibitor. VEN in combination with rituximab (R) is being assessed in an ongoing Phase 1b study.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research